Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio

Fineline Cube Dec 29, 2025
Company Deals

Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal

Fineline Cube Dec 29, 2025
Company Deals

Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing

Fineline Cube Dec 29, 2025
Company Deals

TJ Biopharma Partners with Zhejiang Lab to Develop AI‑Driven Ultra‑Long‑Acting Growth Hormone

Fineline Cube Dec 29, 2025
Company Deals

HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next‑Generation RDCs in Precision Oncology

Fineline Cube Dec 29, 2025
Policy / Regulatory

NMPA Releases 2025 Priority Approval Directory for Eight High-End Medical Device Categories

Fineline Cube Dec 29, 2025
Company Drug

Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China

Fineline Cube Dec 29, 2025
Company Drug

BDgene Doses First Patient with BD920 CRISPR Gene Therapy for HPV-16 HSIL

Fineline Cube Dec 29, 2025
Company Drug

Shanghai Henlius Biotech’s HanSiZhuang Shows Positive Results in Phase III ASTRUM-002 Study

Fineline Cube Nov 1, 2023

Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biopharmaceutical company in China, has unveiled positive...

Company Drug

Luye Pharma Group’s Rivastigmine Patch LY03013 Approved by China’s NMPA for Alzheimer’s Treatment

Fineline Cube Nov 1, 2023

China-based Luye Pharma Group (HKG: 2186) has announced that it has received market approval from...

Company

Bio-Techne Corporation Reports 2% YOY Revenue Growth in Q1 2024 Fiscal Report

Fineline Cube Nov 1, 2023

US-based life sciences service provider Bio-Techne Corporation (NASDAQ: TECH) has released its Q1 report for...

Company Drug

Novartis’ Cosentyx Gains FDA Approval for Hidradenitis Suppurativa Treatment

Fineline Cube Nov 1, 2023

The US Food and Drug Administration (FDA) has issued regulatory approval for Novartis’ (NYSE: NVS)...

Company Deals

AnHeart Therapeutics Signs Exclusive License Deal with Nippon Kayaku for Taletrectinib

Fineline Cube Nov 1, 2023

China-based AnHeart Therapeutics has announced the signing of an exclusive license deal with Japan-based biopharma...

Company Drug

Roche’s Gene Therapy Elevidys Misses Primary Endpoint in DMD Trial

Fineline Cube Nov 1, 2023

Switzerland-headquartered pharmaceutical giant Roche (SWX: ROG) has announced that a Phase III trial for its...

Company Deals

BioLineRx Licenses Multiple Myeloma Drug Motixafortide to Guangzhou Gloria Biosciences

Fineline Cube Nov 1, 2023

Israel’s BioLineRx has entered into a licensing agreement with Guangzhou Gloria Biosciences Co., Ltd., based...

Drug

Amgen Reports Q3 2023 Financials: 5% Growth Driven by Volume Expansion

Fineline Cube Nov 1, 2023

Amgen (NASDAQ: AMGN) has released its Q3 2023 financial results, showcasing a 5% year-on-year (YOY)...

Policy / Regulatory

Guangxi HSA Expands Coverage for Assisted Reproductive Medical Services Under BMI

Fineline Cube Nov 1, 2023

The Healthcare Security Administration (HSA) bureau of the Guangxi Zhuang Autonomous Region has announced a...

Company Medical Device

Siyi Intelligence Secures Approval for Innovative Rehabilitation Robots in China

Fineline Cube Nov 1, 2023

Shanghai-based Siyi Intelligence, a developer of soft rehabilitation robots, has announced that it has received...

Company Deals

Triastek Partners with BASF to Advance 3D Printing Materials for Pharmaceuticals

Fineline Cube Nov 1, 2023

China-based Triastek Inc., a leader in pharmaceutical-focused 3D printing, has announced a strategic partnership with...

Company Deals

Novo Nordisk Acquires Global License for Vect-Horus Molecular Cargo Delivery Platform

Fineline Cube Oct 31, 2023

Novo Nordisk (NYSE: NVO), a leading pharmaceutical company based in Denmark, has obtained an exclusive...

Company Deals

Merck KGaA and Jiangsu Hengrui Ink Strategic Collaboration Deal for Next-Gen PARP1 Inhibitor

Fineline Cube Oct 31, 2023

Germany-based Merck KGaA (NYSE: MRK) has announced the signing of a strategic collaboration deal with...

Company Drug

Coherus’s Loqtorzi Gains FDA Approval for Nasopharyngeal Carcinoma Treatment

Fineline Cube Oct 31, 2023

Coherus Biosciences (NASDAQ: CHRS) executives held an investor conference call on October 30, 2023, to...

Company Drug

Staidson Receives NMPA Approval for Clinical Trial of STSA-1301 in Primary Immune Thrombocytopenia

Fineline Cube Oct 31, 2023

Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204), a China-based pharmaceutical company, has announced that it...

Company Drug

Allist Pharmaceuticals’ Furmonertinib Receives FDA Breakthrough Therapy Designation for NSCLC

Fineline Cube Oct 31, 2023

Shanghai-based biotech Allist Pharmaceuticals Co., Ltd (SHA: 688578) has announced that it has received breakthrough...

Company Drug

Yirui Pharmaceutical’s YR001 Completes Successful Phase I Clinical Study in the US

Fineline Cube Oct 31, 2023

Hangzhou-based Yirui Pharmaceutical Technology Co., Ltd has announced the successful conclusion of a Phase I...

Company Deals

Danyang Huichuang Secures Over USD 13.7 Million in Series B Funding for fNIRS Development

Fineline Cube Oct 31, 2023

Danyang Huichuang Medical Equipment Co., Ltd, a China-based specialist in functional near-infrared spectroscopy (fNIRS), has...

Company Drug

CDE Grants Priority Review to LaNova’s LM-302, Roche’s Alectinib, and Alphamab’s KN026

Fineline Cube Oct 31, 2023

China’s Center for Drug Evaluation (CDE) has indicated that LaNova Medicines’ LM-302, Roche’s (SWX: ROG)...

Company Drug

Boan Biotech Enrolls First Patient in Phase III Study for Opdivo Biosimilar BA1104 in China

Fineline Cube Oct 31, 2023

Boan Biotech (HKG: 6955), a biopharmaceutical company based in China, has announced the enrollment of...

Posts pagination

1 … 387 388 389 … 602

Recent updates

  • Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio
  • Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal
  • Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing
  • Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China
  • BDgene Doses First Patient with BD920 CRISPR Gene Therapy for HPV-16 HSIL
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio

Company Deals

Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal

Company Deals

Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing

Company Drug

Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.